Cargando…

Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age

To describe the pharmacokinetics, safety, and efficacy of etravirine (ETR) in HIV-infected children 1 to less than 6 years of age. DESIGN: Phase I/II, open-label, multicenter, dose-finding study. METHODS: Antiretroviral therapy (ART)-experienced children in two age cohorts (I: 2 to <6 years; II:...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacBrayne, Christine E., Rutstein, Richard M., Wiznia, Andrew A., Graham, Bobbie, Alvero, Carmelita G., Fairlie, Lee, Lypen, Kathryn, George, Kathleen H., Townley, Ellen, Moye, Jack, Costello, Diane G., Reding, Christina A., Barroso Hofer, Cristina, Crauwels, Herta M., Woot de Trixhe, Xavier, Tambuyzer, Lotke, Vanveggel, Simon, Opsomer, Magda, Kiser, Jennifer J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270511/ https://www.ncbi.nlm.nih.gov/pubmed/33831904 http://dx.doi.org/10.1097/QAD.0000000000002902

Ejemplares similares

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
por: Arathoon, Eduardo, et al.
Publicado: (2017)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
por: Orrell, Catherine, et al.
Publicado: (2015)

Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy
por: Woot de Trixhe, Xavier, et al.
Publicado: (2021)

Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus
por: Wu, LS, et al.
Publicado: (2016)

Profile of etravirine for the treatment of HIV infection
por: Tseng, Alice, et al.
Publicado: (2010)

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
por: Mulligan, Nikki, et al.
Publicado: (2016)

1660. Harnessing Handshake Rounds for Infection Prevention: Interventions and Great Catches in the First Year
por: Martinez, Kathleen, et al.
Publicado: (2023)

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
por: Osterholzer, Danielle
Publicado: (2013)

Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity
por: Agneskog, Eva, et al.
Publicado: (2014)

Experimental data of co-crystals of Etravirine and L-tartaric acid
por: Rekdal, Mikal, et al.
Publicado: (2017)

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
por: Mehta, Rashmi, et al.
Publicado: (2018)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network
por: Gebo, Kelly, et al.
Publicado: (2013)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents
por: Chandasana, Hardik, et al.
Publicado: (2023)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection
por: Stellbrink, Hans-Jürgen
Publicado: (2010)

Development of a practical synthesis of etravirine via a microwave-promoted amination
por: Feng, Da, et al.
Publicado: (2018)

Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening
por: Córdova-Bahena, Luis, et al.
Publicado: (2021)

Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
por: Viani, Rolando M
Publicado: (2010)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism
por: Belkhir, Leïla, et al.
Publicado: (2016)

Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE
por: Crauwels, HM, et al.
Publicado: (2010)

634. Incidence of vanC-Mediated Vancomycin-Resistant Enterococcus Bloodstream Infections at Children’s Hospital of Colorado and Implications for Empiric Enterococcal Therapy
por: Dodson, Daniel S, et al.
Publicado: (2019)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
por: Nelson, Mark, et al.
Publicado: (2014)

A quantitative systems pharmacology model for acute viral hepatitis B
por: Asín-Prieto, Eduardo, et al.
Publicado: (2021)

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort
por: Allavena, Clotilde, et al.
Publicado: (2014)

A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance
por: Bañón, Sara, et al.
Publicado: (2014)

Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand
por: Lyons, Alex, et al.
Publicado: (2022)

2207. Impact of an Intervention Bundle on Azithromycin Use and 5-Day Durations of Therapy for Ambulatory Pediatric Community Acquired Pneumonia
por: Weber, Matthew J, et al.
Publicado: (2023)

1666. A Clinical Care Pathway Improves Antibiotic Prescribing in Hospitalized Children with Community Acquired Pneumonia
por: Schweiger, Jennifer, et al.
Publicado: (2023)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Ambulatory cephalosporin prescribing practices at a freestanding children’s hospital network
por: Nguyen-Tran, Hai, et al.
Publicado: (2022)

The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
por: Stellbrink, HJ, et al.
Publicado: (2010)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
por: Kakuda, Thomas, et al.
Publicado: (2012)

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study
por: Teeranaipong, Phairote, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qh4528c4ra5220k1q9shjitft5